Stocks and Investing
Stocks and Investing
Thu, July 18, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, July 17, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Keay Nakae Maintained (ARWR) at Strong Buy and Held Target at $60 on, Jul 17th, 2024
Keay Nakae of Chardan Capital, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy and Held Target at $60 on, Jul 17th, 2024.
Keay has made no other calls on ARWR in the last 4 months.
There are 4 other peers that have a rating on ARWR. Out of the 4 peers that are also analyzing ARWR, 2 agree with Keay's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Andrea Tan of "Goldman Sachs" Initiated at Hold and Held Target at $31 on, Wednesday, June 5th, 2024
- Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $27 on, Monday, May 13th, 2024
These are the ratings of the 2 analyists that currently disagree with Keay
- Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $60 on, Friday, July 5th, 2024
- Alethia Young of "Cantor Fitzgerald" Reiterated at Buy on, Thursday, June 20th, 2024
Contributing Sources